Bibliographic Details
| Title: |
Diabetes gestacional. Una revisión sistemática. |
| Alternate Title: |
Gestational diabetes. A systematic review. |
| Authors: |
Robles Granda, Eliana1, Domo Tomalá, Doris2, Chango Ramírez, Ángel1, Estrada García, Lady1, Yugcha Andino, Germania1, Calderón León, María Fernanda3 dracalderonleon@hotmail.es |
| Source: |
Revista Medicina. 2025, Vol. 25 Issue 1, p14-21. 8p. |
| Subjects: |
TYPE 2 diabetes, GESTATIONAL diabetes, NEONATAL intensive care units, TYPE 1 diabetes, WEIGHT gain |
| Abstract (English): |
Introduction: Gestational diabetes, a common disease in pregnancy, whose prevalence increases in one in six live births worldwide. Materials and methods: A systematic review was developed with the PRISMA 2020 declaration. Results: metformin was superior to insulin in hypoglycemic events. The efficacy, safety of metformin alone or as complementary insulin therapy in pregnancy with gestational diabetes mellitus with diabetes mellitus type 2 reduced maternal weight gain, maternal hypoglycemia, neonatal hypoglycemia, admission to the neonatal intensive care unit and reduction of birth weight 4000 g. Conclusions: Gestational diabetes is related to perinatal morbidity, an increased risk of diabetes and cardiovascular diseases in the future mother and predisposition to childhood obesity in offspring. Metformin reduces the risk of certain maternal and neonatal outcomes compared to insulin therapy [ABSTRACT FROM AUTHOR] |
| Abstract (Spanish): |
Introducción: La diabetes gestacional, enfermedad frecuente en el embarazo, cuya prevalencia aumenta en uno de cada seis nacidos vivos en todo el mundo. Materiales y métodos: Se elaboró una revisión sistemática con la declaración PRISMA 2020. Resultados: metformina fue superior a la insulina en eventos hipoglucémicos. La eficacia, seguridad de la metformina sola o como terapia complementaria a la insulina en el embarazo con diabetes mellitus gestacional con diabetes mellitus tipo 2 redujo el aumento de peso materno, hipoglucemia materna, hipoglucemia neonatal, ingreso a la unidad de cuidados intensivos neonatales y reducción del peso al nacer ≥4000 g. Conclusiones: La Diabetes gestacional se relaciona con morbilidad perinatal, un mayor riesgo de diabetes y enfermedades cardiovasculares en la madre a futuro y predisposición a obesidad infantil en la descendencia. La metformina reduce el riesgo de ciertos resultados maternos y neonatales en comparación con la terapia con insulina. [ABSTRACT FROM AUTHOR] |
|
Copyright of Revista Medicina is the property of Revista Medicina and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
MedicLatina |
